This article is a correction to:
Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
Jing Lu
Jie Gao
Jing Sun1*
Haiping Wang
Qian Huang- 1Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- 2Jinzhou First People’s Hospital, Dalian, China
A Corrigendum on
Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
by Lu J, Gao J, Sun J, Wang H, Sun H, Huang Q, Zhang Y and Zhong S (2023). Front. Pharmacol. 14:1106339. doi: 10.3389/fphar.2023.1106339
In the published article, there was an error in the Funding statement. The funding details for “Jinan Science and Technology Development Plan - Clinical Medicine Technology Innovation Plan (No. 202225049)” were erroneously omitted. The correct Funding statement appears below.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by National Science Foundation for Young Scholars of China (Grant Nos 81500584 and 81200530), Youth Science Foundation of Shandong First Medical University (Shandong Academy of Medical Sciences) (No. 202201-062), the Science and Technology Development Plan Program of Medicine and Health of Shandong Province (No. 202103050761) and Jinan Science and Technology Development Plan - Clinical Medicine Technology Innovation Plan (No. 202225049).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: peritoneal dialysis, peritoneal fibrosis, apolipoprotein A-I, D-4F, oxidative stress, inflammation peritoneal dialysis, inflammation
Citation: Lu J, Gao J, Sun J, Wang H, Sun H, Huang Q, Zhang Y and Zhong S (2024) Corrigendum: Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation. Front. Pharmacol. 15:1532774. doi: 10.3389/fphar.2024.1532774
Received: 25 November 2024; Accepted: 02 December 2024;
Published: 16 December 2024.
Edited and reviewed by:
Weicheng Hu, Yangzhou University, ChinaCopyright © 2024 Lu, Gao, Sun, Wang, Sun, Huang, Zhang and Zhong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jing Sun, c2RkaWFseXNpc0AxMjYuY29t; Haiping Wang, Y2t0d2hwdnZ2QDE2My5jb20=
†These authors have contributed equally to this work and share first authorship